CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S369
DOI: 10.1055/s-0039-1686754
Poster
Rhinology

Shorter hospital stays in epistaxis patients taking Rivaroxaban and Apixaban vs. Phenprocoumon

P Stankovic
1   HNO Klinik, SANA Kliniken Leipziger Land, Borna
,
C Frommelt
1   HNO Klinik, SANA Kliniken Leipziger Land, Borna
,
S Hammel
1   HNO Klinik, SANA Kliniken Leipziger Land, Borna
,
R Georgiew
1   HNO Klinik, SANA Kliniken Leipziger Land, Borna
,
J Wittlinger
1   HNO Klinik, SANA Kliniken Leipziger Land, Borna
,
D Obradovic
2   Herzzentrum Leipzig, Leipzig
,
S Hoch
3   Uni Klinik Marburg, Marburg
,
N Dagres
2   Herzzentrum Leipzig, Leipzig
,
T Wilhelm
1   HNO Klinik, SANA Kliniken Leipziger Land, Borna
› Author Affiliations
 

Introduction:

Patients under oral anticoagulants (OAC) currently represent 1/3 of all patients treated for epistaxis with an expected upward trend. New oral anticoagulants (DOAC) with a different mechanism of action in comparison to Vitamin-K antagonists (VKA) are on the market just under a decade ago. DOAC are favoured by the current guidelines in comparison to VKA, meaning an increase of their presence in the near future. There are barely studies that investigate the impact of DOAC on patients with epistaxis.

Methods:

A retrospective study was performed analysing all patients treated stationary for epistaxis from 01.01.2011 to 01.01.2018 at the SANA Kliniken Leipziger Land, Germany.

Results:

From a total of 540 patients, 40.8% were under OAC. DOAC surpassed VKA in the last two years of observation. The length of hospital stay was significantly longer in the phenprocoumon group (2.98 ± 1.72 days) in comparison with both rivaroxaban (2.6 ± 1.38) and apixaban (2.23 ± 0.61) groups (p = 0.02), whereas no difference was noted between the latter two. Posterior epistaxis was more often in the phenprocoumon group (8.6%) in comparison to rivaroxaban (0%) and apixaban (0%) (p = 0.03). Hospital stays longer than 5 days signified a probability of recurrence of more than 50%.

Conclusion:

Shorter hospital stays and exclusively anterior bleeding was noted in patients taking rivaroxaban and apixaban, whereas patients taking phenprocoumon stayed longer in hospital and had more posterior bleedings.



Publication History

Publication Date:
23 April 2019 (online)

© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Stuttgart · New York